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Abstract
Objective—The challenges posed by people living with multiple chronic conditions are unique 
for people with dementia and other significant cognitive impairment. There have been recent calls 
to action to review the existing literature on co-occurring chronic conditions and dementia in order 
to better understand the effect of cognitive impairment on disease management, mobility, and 
mortality.
Methods—This systematic literature review searched PubMed databases through 2011 (updated 
in 2016) using key constructs of older adults, moderate-to-severe cognitive impairment (both 
diagnosed and undiagnosed dementia), and chronic conditions. Reviewers assessed papers for 
eligibility and extracted key data from each included manuscript. An independent expert panel 
rated the strength and quality of evidence and prioritized gaps for future study.
Results—Four thousand thirty-three articles were identified, of which 147 met criteria for 
review. We found that moderate-to-severe cognitive impairment increased risks of mortality, was 
associated with prolonged institutional stays, and decreased function in persons with multiple 
chronic conditions. There was no relationship between significant cognitive impairment and use of 
cardiovascular or hypertensive medications for persons with these comorbidities. Prioritized areas 
for future research include hospitalizations, disease-specific outcomes, diabetes, chronic pain, 
cardiovascular disease, depression, falls, stroke, and multiple chronic conditions.
Conclusions—This review summarizes that living with significant cognitive impairment or 
dementia negatively impacts mortality, institutionalization, and functional outcomes for people 
living with multiple chronic conditions. Our findings suggest that chronic-disease management 
interventions will need to address co-occurring cognitive impairment.
Keywords
dementia; cognitive impairment; multiple chronic conditions; systematic literature review; public 
health; aging
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There are currently 44 million people living with dementia worldwide (5 million in the U.S. 
(Hebert et al., 2013), with numbers expected to more than triple by 2050 (Prince et al., 
2013). Dementia is the largest single contributor to disability and needs for care among older 
adults out of any chronic disease (Wimo and Prince, 2010), and total monetary costs of 
dementia represent a similar financial burden as heart disease and cancer (Hurd et al., 2013). 
Dementia has recently been identified as an important chronic condition (CC) to target for 
public health interventions (Machlin and Soni, 2009; Goodman et al., 2013).
Current increases in the numbers of older adults and prevalence of CCs as leading causes of 
death have led to the recognition of the challenges faced by people living with multiple CCs 
(Goodman et al., 2013). A growing body of evidence indicates a higher burden of CCs in 
older adults with dementia (Hill et al., 2002; Bynum et al., 2004); recent U.S. Medicare 
beneficiary data suggest that one in four persons with dementia have co-occurring stroke 
(24%) and one in three have co-occurring coronary artery disease (33%) (National Academy 
on an Aging Society, 2000). People in more advanced stages of dementia often have 
difficulty recognizing and reporting symptoms and/or side effects, adhering to medication, 
and complying with treatment and follow-up recommendations because of deficits in 
memory, language, judgment, and reasoning ability (McGuire et al., 2006; Boustani et al., 
2007; Arlt et al., 2008; Punthakee et al., 2012). Older adults with dementia also have higher 
health care expenditures than those without impairment (Hill et al., 2002; Frytak et al., 2008; 
Kuo et al., 2008; Zhao et al., 2008; Marengoni et al., 2009; Suehs et al., 2013). At the same 
time, persons with multiple CCs consume a disproportionate number of health care (Thorpe 
et al., 2010; Centers for Medicare and Medicaid Services (CMMS), 2012), and more care 
coordination and greater self-management skills are required for those with multiple CCs 
(Redelmeier et al., 1998; Committee on Quality of HealthCare in America, 2001).
A better understanding is needed to better understand the relationships between dementia 
and co-occurring CCs from a public health standpoint. The Healthy Brain Initiative: The 
Public Health Road Map for State and National Partnerships, 2013–2018 ((Alzheimer’s 
Association (AA) and Centers for Disease Control and Prevention (CDC), 2013) has called 
for “A review of the literature on co-occurring CCs and dementia, including Alzheimer’s 
disease, to understand the effect of dementia on various outcomes such as depression, 
disease management, morbidity, and mortality.” This systematic literature review examines 
the effects of moderate-to-severe cognitive impairment (including both diagnosed and 
undiagnosed dementia) on co-occurring CCs to document what is currently known and what 
gaps remain in the research literature.
Methods
This review was guided by a multidisciplinary seven-member expert panel of health services 
and cognitive health researchers from around the U.S. The conceptual framework (Figure 1) 
was developed based on the National Institutes of Health (NIH) Cognitive and Emotional 
Health Project, which identified how moderate-to-severe cognitive impairment might 
influence co-occurring CCs through shared risk factors (such as hypertension) and/or disease 
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management (such as symptom recognition, reporting, or treatment adherence) (NIH, 2001; 
Hendrie et al., 2006). Outcomes of interest include disease-specific outcomes (e.g., recurrent 
strokes for persons with moderate to severe cognitive impairment and a history of stroke), 
healthcare costs (e.g., outpatient or inpatient care costs), service utilization (e.g., 
hospitalizations and institutionalizations), mortality, and function.
Review methods were derived from the Guide to Community Preventive Services “The 
Guide” (Briss et al., 2000; Norris et al., 2002) and previously conducted systematic reviews 
(Frederick et al., 2007; Snowden et al., 2011), and align with PRISMA guidelines (Moher et 
al., 2009). We searched peer-reviewed literature from inception (1967) through 2011 using 
PubMed. Subject headings and text words reflected key constructs of older adults, moderate-
to-severe cognitive impairment, and CCs (Table 1). References to meta-analyses, review 
papers, and included articles were also examined to identify possible articles.
Inclusion/exclusion criteria
Study inclusion criteria were: (i) sample size of 100 or more; (ii) participants aged 50 and 
older, (iii) data on populations both with and without moderate to severe cognitive 
impairment; (iv) a valid and reliable measure of dementia or moderate-to-severe cognitive 
impairment; (v) at least one other CC or geriatric syndrome or measure of comorbidity; and 
(vi) a description of the prevalence or effect of cognitive impairment on co-occurring CCs.
To define cognitive impairment, the article must include a valid and reliable clinical 
diagnosis of dementia (e.g., the Diagnostic Statistical Manual criteria, fourth edition (DSM-
IV) (American Psychiatric Association, 2000); the National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA) criteria for Alzheimer’s disease (McKhann et al., 1984); or 
the National Institute of Neurological Disorders and Stroke and Association Internationale 
pour la Recherché et l’Enseignement en Neurosciences (NINDS-AIREN) criteria for 
vascular dementia (Erkinjuntti, 1994) or valid and reliable measures of moderate-to-severe 
cognitive impairment that captured memory and at least one other cognitive domain such as 
executive function or language. These could include both multidimensional measures (e.g., 
Mini-Mental Status Examination (MMSE)) (Folstein et al., 1975) or multiple individual 
measures of cognitive function with at least one focused on memory. The review focused on 
moderate-to-severe cognitive impairment, including persons with and without official 
dementia diagnoses. We included the latter group given the high rate of persons without a 
formal diagnosis; currently, less than half of those in high income countries and less than 
10% in low-income and middle-income countries have received a dementia diagnosis 
(Prince et al., 2013).
Using the definition of CCs as “conditions that last a year or more and require ongoing 
medical attention and/or limit activities of daily living (ADL’s)” (Warshaw, 2006; US 
DHHS, 2010) the expert panel created a list of common CCs (Table 2) from The NIH 
Cognitive and Emotional Health Project (Hendrie et al., 2006), the U.S. DHHS multiple 
chronic conditions (MCC) Strategic Framework (US DHHS, 2010), and disease categories 
in PubMed. Geriatric syndromes (e.g., frailty and polypharmacy) were included as well 
given their large impact on quality of life and disability (Inouye et al., 2007). Geriatric 
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syndromes are conditions that are common in older adults but do not fit into discrete disease 
categories (Ahmed et al., 2007; Inouye et al., 2007; Chaudhry et al., 2010). To be included 
in this review, the article had to include people living with at least one CC condition or 
geriatric syndrome (Table 2), or evidence of co-morbid conditions via a valid and reliable 
measure of comorbidity (e.g., Charlson’s Comorbidity Index) (Charlson et al., 1987).
Articles included both community-based and institutionalized populations from around the 
globe. We excluded articles not published in English, that only used an ICD diagnosis for 
cognitive impairment or dementia, that defined cognitive impairment as delirium, traumatic 
brain injury, developmental disorders, or MCI, and that reported only reviews, 
commentaries, or meta-analyses.
Data collection
We used a two-step screening process to assess whether articles met inclusion criteria. We 
first reviewed titles and abstracts. Articles that could not be included or excluded based on 
abstracts were retrieved to examine the full text in a second screening phase. Screening of 
titles and abstracts was conducted jointly by members of the research team (LS, LB, and 
CC) until 80% agreement was reached; subsequent title and abstract screening was 
conducted separately. Articles were screened by individual reviewers. A different research 
team member abstracted data from accepted articles to double check whether an article met 
eligibility criteria. The reviewers met weekly to discuss title/abstract and article screening. 
The principal investigator (MS) made final determinations when questions or disagreements 
between reviewers could not be resolved.
Rating the evidence
We used a standardized form to systematically collect data from each article, including study 
design, sample size, setting, co-occurring chronic disease, outcome measures, results, and 
indicators of study quality (e.g., adjustment for possible confounders). Data were compiled 
in summary tables for evidence rating (see Appendices). We grouped articles into chronic 
condition-outcome pairings to categorically rate the evidence, and panelists rated the overall 
evidence within each group; for example, rating the evidence for how cognitive impairment 
impacted mortality for persons with multiple CCs, stroke, or depression.
Expert panel members rated both the quality and strength of evidence across articles in each 
chronic condition-outcome pairing using a qualitative approach from previous systematic 
literature reviews (Frederick et al., 2007; Snowden et al., 2011). Indicators of quality 
included sample size and generalizability, appropriate measurement of cognitive impairment 
and of CCs, use of multivariable analysis, and controlling specifically for age, gender, and 
education. For quality rating, panel members independently rated each condition-outcome 
pairing as “good”, “fair”, or “limited”.
Indicators of strength of evidence included the study quality and design, the number of 
studies in the chronic condition-outcome pairing, consistency across studies, and statistical 
findings. For strength of evidence ratings, the panel members independently rated each 
condition-outcome pairing as “strong”, “sufficient”, or “insufficient” (recording whether the 
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insufficient rating was due to an insufficient number of at least fair quality studies or a 
sufficient number of available studies but inconclusive data).
Final determination of quality and strength of evidence was based on 80% agreement among 
panel members (i.e., agreement among six out of the seven panelists). The panel met to 
discuss areas of disagreement, and panel members were allowed to change their votes after 
the discussion; however, to reduce persuasion bias, they were not required to reach 
consensus.
Identifying and prioritizing gaps where evidence was rated “insufficient”
The panel also identified and prioritized the areas for which there was insufficient evidence. 
We used Q-sort ranking (Brown, 1996), a method for rank-ordering items, to prioritize the 
gaps in which panelists assigned a rank (“5”=highest priority to “1”=least priority) to each 
of the 42 outcomes and CCs/geriatric syndromes with insufficient evidence in order of 
priority for further research (“5”=highest priority to “1”=least priority). Using the Q-sort 
method, informants were given a limited, normally distributed allotment of 1s, 2s, 3s, 4s, 
and 5s to create a normal distribution of rankings.
Results
Four thousand thirty-three articles were identified in the literature review: 4,005 in the 
PubMed search and 28 from reference lists of review articles or meta-analyses (Figure 2). 
Forty-eight articles met inclusion criteria after Level 1 screening of abstracts, and 99 articles 
met inclusion criteria after Level 2 screening of abstracts, yielding 147 included articles. 
Articles were excluded primarily due to small sample size or the omission of both persons 
with and without dementia/cognitive impairment.
The 147 included articles were grouped into 62 chronic condition-outcome pairings, or 
categories, for rating the evidence. Nine percent (N = 7) of the categories were rated as 
having sufficient evidence (Table 3); all of which were rated at least fair quality. Sufficient 
evidence was found for the impact of moderate-to-severe cognitive impairment on mortality, 
length of stay in institutional settings, function, and cardiovascular medication use, for 
persons with certain co-occurring CCs. The other pairings were deemed to have insufficient 
evidence, due to lack of studies (two or fewer) or inconclusive evidence (mixed results 
within or across studies) (Table 4).
Mortality
Twenty-nine studies (Kukull et al., 1994; Arfken et al., 1995; Bruce et al., 1995; Gale et al., 
1996; Agüero-Torres et al., 1999; Foley et al., 1999; Kammoun et al., 2000; Helmer et al., 
2001; Stump et al., 2001; Freels et al., 2002; Ganguli et al., 2002; Feil et al., 2003; Nguyen 
et al., 2003; Tschanz et al., 2004; Cacciatore et al., 2005; Fitzpatrick et al., 2005; Magaziner 
et al., 2005; Bursi et al., 2006; Guhne et al., 2006; Llinàs-Regla et al., 2007; Lyketsos et al., 
2007; Meerman et al., 2008; Rothman et al., 2008; Zekry et al., 2009; Lavretsky et al., 2010; 
Wang et al., 2010a; Gombojav et al., 2011; Millán-Calenti et al., 2011; Nikolova et al., 
2011) compared mortality rates for persons with multiple CCs and with and without 
moderate-to-severe cognitive impairment or dementia. Seventeen used community-based 
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samples and 12 used clinic-based samples. Most studies had a sample size greater than 500 
(79%) with 52,644 subjects across all studies. A majority of studies used a multivariable 
analysis (90%) and almost half of these (46%) adjusted for age, gender, and education (the 
remaining studies adjusted for just one or two of these demographic covariates).
Mortality was measured in terms of mortality rates, risk for mortality (e.g., hazard ratios 
(HRs)), or survival rates. Percent mortality ranged from 40.2% to 82% for persons with 
moderate-to-severe cognitive impairment and 16.0% to 37.7% for persons without 
significant cognitive impairment (Stump et al., 2001; Nguyen et al., 2003; Tschanz et al., 
2004; Guhne et al., 2006; Llinàs-Regla et al., 2007; Lavretsky et al., 2010; Wang et al., 
2010a). Six studies (Bruce et al., 1995; Stump et al., 2001; Fitzpatrick et al., 2005; Llinàs-
Regla et al., 2007; Meerman et al., 2008; Lavretsky et al., 2010) reported unadjusted relative 
risks (RR) for mortality (95% confidence interval (CI)), ranging from 2.3 (1.7–3.2) (Llinàs-
Regla et al., 2007) to 7.4 (4.9–11.4) (Lavretsky et al., 2010).
Fourteen studies (Helmer et al., 2001; Stump et al., 2001; Freels et al., 2002; Feil et al., 
2003; Nguyen et al., 2003; Tschanz et al., 2004; Fitzpatrick et al., 2005; Bursi et al., 2006; 
Guhne et al., 2006; Llinàs-Regla et al., 2007; Meerman et al., 2008; Rothman et al., 2008; 
Lavretsky et al., 2010; Gombojav et al., 2011) reported the adjusted HR for significant 
cognitive impairment on risk of mortality (95% CI) ranging from 1.5 (1.1–2.1) (Rothman et 
al., 2008) to 2.99 (2.53–3.53) (Tschanz et al., 2004); covariates may have included 
demographics, CCs, and six other frailty criteria (Rothman et al., 2008). The percent 
attributable risk (PAR%) of death related to dementia diagnosis ranged from 11.8% (Guhne 
et al., 2006; Llinàs-Regla et al., 2007) to 16.6% (Tschanz et al., 2004). Tschanz (Tschanz et 
al., 2004) and Feil (Feil et al., 2003) compared mortality RR and PAR for dementia versus 
other CCs: In addition, two studies (Feil et al., 2003; Tschanz et al., 2004) found that 
dementia or moderate-to-severe cognitive impairment had a greater RR of mortality than 
other CCs (e.g., an RR two to three times higher) and higher mortality PAR% than other 
CCs.
In addition, persons with moderate-to-severe cognitive impairment had shorter average 
survival times, ranging from 3.0 to 7.1years compared with 4.0 to 11.0years for persons 
without cognitive impairment (Agüero-Torres et al., 1999; Fitzpatrick et al., 2005; Guhne et 
al., 2006; Lavretsky et al., 2010; Wang et al., 2010a). Persons with moderate-to-severe 
cognitive impairment also had lower survival rates: the adjusted 5-year survival for persons 
with moderate-to-severe cognitive impairment was 16.1% versus 28.5% for normal 
cognition (Wang et al., 2010a); unadjusted survival rates were 22% versus 39% (Bursi et al., 
2006) and lower (poorer) scores on the MMSE decreased likelihood of survival (Bruce et al., 
1995).
Several studies reported non-significant or negative relationships. For example, in 2005, 
Magaziner et al., (2005) reported an unadjusted RR for mortality of 0.61 (0.53–0.71) and 
adjusted RR for mortality of 0.63 (0.51–0.77) for persons with dementia and multiple CCs. 
This study included persons living in nursing homes (N = 2,153, mean age > 80), almost half 
of which were diagnosed with dementia using DSM criteria. In this study, the group without 
dementia included people who were difficult to diagnose.
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The expert panel also found sufficient evidence that moderate-to-severe cognitive 
impairment increases mortality in persons with Parkinson’s disease (Ebmeier et al., 1990; 
Marder et al., 1991; Mitchell and Rockwood, 2000; Levy et al., 2002; Parashos et al., 2002; 
Buter et al., 2008; Lo et al., 2009; Hobson et al., 2010, N = 4,513) and stroke (Tatemichi et 
al., 1994; Desmond et al., 1998; Desmond et al., 2002; Liebetrau et al., 2003; Melkas et al., 
2009; Oksala et al., 2009, N = 2,302). These were the only specific co-occurring CCs for 
which sufficient evidence was found to examine mortality outcomes. Other articles included 
people with dementia or moderate-to-severe cognitive impairment from various etiologies 
(stroke, Parkinson’s disease, and other).
Service utilization
Three studies (Smith et al., 2000; Magaziner et al., 2005; Rothman et al., 2008, (N = 3,423) 
examined length of stay in an institution for persons with multiple CCs (Inouye et al., 2007). 
In 2008, Rothman et al., (2008) reported an adjusted HR for long-term nursing home stay of 
3.7 (95% CI) 2.5–5.4) for persons with cognitive impairment (MMSE < 24) versus those 
without impairment. In 2000, Smith et al., (2000) found an unadjusted median length of stay 
in nursing homes for those with dementia (diagnosed using DSM-III-R criteria) of 946 days 
compared with those without dementia at 579days. Lastly, Magaziner and colleagues 
reported a decreased likelihood of being discharged to home (adjusted RR of 0.23 (95% CI 
0.17–0.31)) for those with dementia (DSM-III-R criteria) compared with those without.
Function
Nineteen studies (Agüero-Torres et al., 1998; Zhu et al., 1998; Agüero-Torres et al., 2002; 
Covinsky et al., 2003; Lyketsos et al., 2005; Magaziner et al., 2005; Lyketsos et al., 2007; 
Cankurtaran et al., 2008; Rothman et al., 2008; Zekry et al., 2008; Huang et al., 2009; Sousa 
et al., 2009; Stewart et al., 2009; Zekry et al., 2009; Feng et al., 2010; Wang et al., 2010b; 
Gombojav et al., 2011; Millán-Calenti et al., 2011; Nikolova et al., 2011) (N = 37,466) 
examined the impact of significant cognitive impairment and co-occurring multiple 
comorbidities on function. Function was typically defined as basic activities of daily living 
(ADL’s) or instrumental ADL’s (IADLs). Nine studies included samples with a dementia 
diagnosis and seven included institutionalized persons. Half of the studies used multivariable 
analysis, with half of these adjusting for age, sex, and education. Persons with dementia and 
multiple CCs had significantly more IADL and ADL impairments than those without 
significant cognitive impairment.
Medication use
Seven studies (Freels et al., 2002; Lopponen et al., 2005; Bursi et al., 2006; Rastas et al., 
2007; Andersson et al., 2008; Barzilay et al., 2008; Cankurtaran et al., 2008) (N = 5,245) 
examined the degree to which dementia affected cardiovascular medication use (other than 
that for hypertension) in persons with co-occurring cardiovascular disease (CVD). Only one 
(Barzilay et al., 2008) found statistically significant differences between people with 
dementia (VaD, AD, and not otherwise specified) and use of CVD medications such as beta-
blockers, ACE inhibitors, or aspirin.
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In addition, the expert panel agreed on sufficient evidence that moderate-to-severe cognitive 
impairment had no impact on hypertension medication use in people with co-occurring 
hypertension (Freels et al., 2002; Hanon et al., 2006; Barzilay et al., 2008; Vinyoles et al., 
2008; Huang et al., 2009; Stewart et al., 2009; Gombojav et al., 2011) with five of the seven 
studies (Freels et al., 2002; Hanon et al., 2006; Huang et al., 2009; Stewart et al., 2009; 
Gombojav et al., 2011) (N = 8,236) reporting no statistically significant differences for 
persons with and without moderate-to-severe cognitive impairment.
Prioritizing the gaps in the evidence
The expert panel identified 55 pairings with insufficient or no evidence (Table 4). These 
included 18 outcomes (e.g., cost and function) and 10 CCs or geriatric syndromes (e.g., 
cancer and chronic obstructive pulmonary disease (COPD)) with insufficient evidence, and 
no evidence was found for the impact of significant cognitive impairment on 14 additional 
conditions/syndromes: asthma, arthritis, bone diseases, chronic kidney disease, chronic pain, 
dental problems, other chronic mental illness, neurological conditions, sleep disorders, 
substance abuse, risk factors if another CC was present (e.g., obesity and smoking), frailty, 
functional impairments, and urinary incontinence.
After the expert panel prioritized these gaps, the following were identified as highest priority 
for future research: service utilization-hospitalizations and disease-specific outcomes, and 
diabetes, chronic pain, CVD, depression, falls or fractures, stroke, and multiple CCs (the 
presence of moderate-to-severe cognitive impairment and more than two other CCs).
Updating the review
We were recently asked to update the literature review to include more recent articles 
published between mid-2011 and June of 2016. Twenty-two additional articles met our 
criteria and two new chronic condition-outcome pairings had sufficient evidence. The first 
looked at the impact of cognitive impairment and co-occurring CVD on mortality. Two 
studies (O’Donnell et al., 2012 and Huijts et al., 2013) found an over 50% increase in 
mortality risk for people living with moderate-to-severe cognitive impairment (adjusted HRs 
1.53 (95% CI 1.02–2.30) to 1.68 (1.49–1.90)). The second new outcome was disease-
specific; namely that living with dementia and diabetes increased the risk for severe 
hypoglycemia compared with persons living with diabetes and without dementia 
(Abbatecola et al., 2015; Prinz et al., 2015). Fourteen new articles (Chang et al., 2012; Chen 
et al., 2014; Huijts et al., 2013; Llibre et al., 2014; Katsoulis et al., 2014; Lee et al., 2015; 
Mignardot et al., 2014; Murao et al., 2014; O’Donnell et al., 2012; Park et al., 2016; Sanyal 
et al., 2014; Warchol-Celinska et al., 2015; van Asch et al., 2013) fell into existing chronic 
condition-outcome pairings and did not change the quality or strength of the evidence, and 
four articles (Hawkins et al., 2012; Jacobs et al., 2012; Hajduk et al., 2013; Provencher et al., 
2015) were found in separate areas where there was previously no evidence.
Discussion
This review found sufficient evidence that moderate-to-severe cognitive impairment 
(including both diagnosed and undiagnosed dementia) in the presence of co-occurring CCs 
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had a significant effect on increasing mortality, increasing length of stay in institutional 
settings, and decreasing function. In addition, there was sufficient evidence that moderate-to-
severe cognitive impairment was not associated with cardiovascular or hypertension 
medication use. For all other outcome-chronic condition pairings, the panel found 
insufficient evidence or no evidence.
Previous studies in older adults have identified multiple risk factors for co-occurring 
cognitive decline and other CCs such as CVD (NIH, 2001). Comparisons between older 
adults with significant cognitive impairment and those without suggest that the former tend 
to be sicker and more likely to suffer from multiple CCs and greater functional impairment 
(Hill et al., 2002; Bynum et al., 2004; Frytak et al., 2008; Kuo et al., 2008; Zhao et al., 2008; 
Marengoni et al., 2009). The current review partially confirmed these earlier findings 
(specifically for risks of mortality, institutional length of stay, and decreased function) and 
further affirmed that significant cognitive impairment itself may have an impact on the 
subsequent development of other CCs and syndromes in older adults. Most of the sufficient 
evidence found in this review was for moderate-to-severe cognitive impairment and multiple 
CCs; there was insufficient evidence to support a relationship between significant cognitive 
impairment and course of specific CCs (e.g., depression).
Moderate-to-severe cognitive impairment (including both diagnosed and undiagnosed 
dementia) is associated with clinical deterioration. Significant cognitive impairment also 
makes it more likely that individuals will not recognize or respond appropriately to early 
symptoms of CCs, geriatric syndromes, and decreasing function. Greater severity of illness 
at diagnosis and the inability to maintain medication regimens and management of side 
effects may lead, at least in part, to the increased costs of health care for older adults with 
significant cognitive impairment compared with those without (Gutterman et al., 1999). 
Policies and procedures that improve surveillance among those with significant cognitive 
impairment may encourage timely diagnosis and treatment that with sufficient support can 
reduce severity and promote improved health. In addition, the assessment of cognitive 
abilities in those with multiple CCs would potentially assist health care providers in 
improved disease management. Although it is perhaps reassuring that difficulty managing 
medications does not appear to affect access to them, affected individuals may need 
additional supports to maintain control over their conditions.
Reviewing existing evidence and identifying gaps is the first step toward assisting clinicians, 
investigators, and policy makers at international, national, and local levels to understand the 
effects of significant cognitive impairment on CCs, and then design and deliver relevant 
evidence-based programs for disease management. Several national entities such as the 
NIH’s Cognitive and Emotional Health Project (NIH, 2001; Hendrie et al., 2006) and the 
CDC’s Healthy Brain Initiative (CDC and the AA, 2007; AA and CDC, 2013) emphasize 
the identification and use of existing datasets to answer these important research gaps. Our 
research team and advisory committee created an inventory of existing major datasets that 
include measures of both cognitive impairment and CCs (Bell et al., 2015); these datasets 
can be used to conduct secondary data analyses to address research gaps identified by our 
review team (e.g., Snowden et al, 2015). Findings from this review can also inform Healthy 
People 2020 objectives’ (US DHHS ODPHP, 2010) to increase the proportion of older adults 
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with one or more CCs who report confidence in managing their conditions, and to decrease 
the numbers of preventable hospitalizations (many for co-occurring CCs) for people living 
with Alzheimer’s disease and other dementias.
The strengths of this systematic review are its focus on the effects of significant cognitive 
impairment on CCs, the use of a formal process derived from the Guide to Community 
Preventive Services (Briss et al., 2000; Norris et al., 2002), an experienced study team 
(Frederick et al., 2007; Snowden et al., 2011), and input from a multidisciplinary expert 
panel to identify relevant studies, assess quality, and summarize the evidence. There is far 
more literature to date that looks at how CCs impact moderate-to-severe cognitive 
impairment. In practice, it is important to consider both, or bidirectionality (Mercer et al., 
2012)-that physical conditions can affect mental conditions, and vice versa. Concordant 
conditions, such as stroke and cognitive impairment, are those in which management of one 
of these conditions is likely to impact management for the other CC.
This review has several limitations. While we aligned with most PRISMA recommended 
guidelines (Moher et al., 2009), we did not assess for risk of bias within and across studies. 
We did provide our expert panel with details on study design, sample, measures, analysis, 
and outcomes in order to inform their ratings of the strength and quality of evidence. 
Second, we reviewed only one database (PubMed) due to limitations on time and resources 
to conduct the review. This database was chosen given our focus on the public health 
implications of addressing both cognitive impairment and co-occurring CCs together. In 
addition, we recognize the complexity of including function both as a key outcome of 
interest and a geriatric syndrome, in light of functional impairment being part of the criteria 
for a dementia diagnosis. While complicated, function (and functional impairments) was 
viewed as important outcomes of interest given their significant impact on chronic disease 
management which in turn impacts other outcomes such as mortality and service utilization. 
Similarly, because Parkinson’s disease and stroke are established causes of dementia with 
their own significant mortality risk, our finding of increased mortality in these conditions 
may be expected. Finally, our exclusion criteria, in particular the exclusion of MCI as a 
potential contributor to other CCs, may have eliminated potentially informative studies, but 
the expert panel found the lack of an established definition or screening criteria too vague 
for its evaluation as a contributing factor.
Key findings from this review include the significant impact of cognitive impairment on 
mortality, service utilization, and functional outcomes for people living with co-occurring 
CCs, and that there was not strong evidence to support the association between moderate-to-
severe cognitive impairment and medication use for co-occurring CCs. In addition, this 
review identified and prioritized gaps in the evidence to help guide future research including 
secondary data analyses. The results of this systematic review and the identification of gaps 
in the literature will strengthen the ability of clinicians, researchers, and policy makers to 
respond to the growing burden of CCs in older adults attributable to increasing rates of 
cognitive impairment.
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• Living with significant cognitive impairment and co-occurring CCs is an 
important issue for public health in aging society.
• Little is known about how dementia and other significant cognitive 
impairment impacts morbidity, mortality, and other outcomes for people with 
multiple CCs.
• This systematic review found sufficient evidence that moderate to severe 
cognitive impairment (including dementia) increased risks of mortality, was 
associated with prolonged institutional stays, and decreased function in 
persons with multiple CCs. There was no relationship between significant 
cognitive impairment and use of cardiovascular or hypertensive medications 
for persons with these comorbidities.
• Further study is needed to better understand how dementia and other 
significant cognitive impairment influences hospitalizations, disease-specific 
outcomes, diabetes, chronic pain, CVD, depression, falls, and stroke for 
people living with multiple CCs.
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Conceptual Framework. [Colour figure can be viewed at wileyonlinelibrary.com]
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Literature search flow chart.
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Pulmonary disease, chronic obstructive[Majr] Multiple sclerosis[Majr]
Emphysema[Majr] Bone diseases[Majr]
Diabetes mellitus[Majr] Chronic pain[tiab]
Cardiovascular diseases[Majr] Osteoarthritis[Majr]
cardiovascular disease[tiab] Frailty[tiab]
Intracranial arterial Diseases[Majr] Epilepsy[Majr]
Carotid artery diseases[Majr] Brain ischemia[Majr]
Hypertension[tiab] Stroke[Majr]
Heart disease[tiab] Sleep disorders[Majr]
Neoplasms[Majr] Oral health[Majr]
Parkinsonian disorders[Majr] Urinary incontinence[Majr]
Asthma[Majr] Osteoporosis[Majr]
Substance-related disorders[Majr] Comorbidity[Majr]
Stress disorders, Post-traumatic[Majr] co-morbidity[tiab]
Bipolar disorder[tiab] comorbidity[tiab]
Manic depressive disorder[tiab] Chronic disease[Majr]
Study design Cross-sectional studies[Mesh] OR cross-sectional stud*[tiab] OR cohort studies[Mesh] OR cohort stud*[tiab] OR 
case–control studies[Mesh] OR case–control stud*[tiab] OR longitudinal stud*[tiab] OR longitudinal stud*[tiab] 
OR prospective stud*[tiab] OR retrospective stud*[tiab]
[Mesh], Medical subject headings; [mh] is used to search a MeSH heading; [majr] is used to search a MeSH heading that is a major topic of an 
article; [tiab], Title or abstract.
a
Note: Limits of English-only studies were also set.
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Table 2
Chronic conditions and geriatric syndromes
Chronic conditions Geriatric syndromes
Asthma Falls, fractures, and other injuries
Arthritis Frailty
Bone diseases (e.g., osteoporosis) Functional impairments
Brain diseases (e.g., Parkinson’s) Polypharmacy/High-risk medications
Cancer Urinary incontinence
Cardiovascular diseases (e.g., CAD, hypertension, and hyperlipidemias)




Depression and other chronic mental illness (PTSD, schizophrenia, and bipolar)
Diabetes
Emphysema/COPD
Neurological conditions (epilepsy and multiple sclerosis)
Sleep disorders
Substance abuse
Risk factors if a chronic conditions is present (e.g., obesity, smoking, and gait)
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Table 4
Summary of evidence rating for chronic condition-outcome pairings with insufficient evidence due to not 
enough studies. Categories with insufficient evidence due to mixed or inconclusive findings are listed in 
italics)
Outcome Chronic condition # of studies Sample size Author, Year
Mortality
Mortality Depression 4 3,283 Arfken et al., 1995; Lavretsky et al., 2010; Millán-
Calenti et al., 2011; St. John and Montgomery, 2009
Mortality Cancer 2 3,278 Robb et al., 2010; Roe et al., 2010
Mortality Atrial Fib 1 2,837 Miyasaka et al., 2007
Mortality CHF 1 142 Haydar et al., 2004
Mortality COPD 1 134 Antonelli-Incalzi et al., 2006
Mortality Hip fracture 1 558 Cree et al., 2000
Mortality Hypertension 1 2,496 Gombojav et al., 2011
Service utilizations/institutionalizations
Hospitalizations MCC 3 13,334 Feil et al., 2003; McCormick et al., 2001; Welmerink 
et al., 2010
Hospitalizations Cancer 1 3,020 Roe et al., 2010
Hospitalizations CHD 2 7,188 Bursi et al., 2006; Welmerink et al., 2010
Hospitalizations Diabetes 1 789 Sinclair et al., 2000
Length of stay, hospital MCC 2 1,343 Lang et al., 2006; Zekry et al., 2009
Other medical care MCC 2 779 McCormick et al., 1994; McCormick et al., 2001
Other medical care Cancer 1 258 Robb et al., 2010
Other medical care Diabetes 2 1,188 Quinn et al., 2009; Sinclair et al., 2000
Other medical care Myocardial infarction 1 1,832 Bursi et al., 2006
Institutionalization/NH MCC 4 2,361 Guhne et al., 2006; Meerman et al., 2008; Smith et 
al., 2000; Zekry et al., 2009
Institutionalization/NH Diabetes 1 789 Sinclair et al., 2000
Institutionalization/NH Hip fracture 1 558 Cree et al., 2000
Institutionalization/NH Parkinson’s disease 1 178 Parashos et al., 2002
Length of stay, institution/NH Diabetes 1 399 Quinn et al., 2009
Amount of care at institutions MCC 1 198 Lyketsos et al., 2007
Home care MCC 1 435 Zekry et al., 2009
Home care Diabetes 1 789 Sinclair et al., 2000
Caregiver burden MCC 1 198 Lyketsos et al., 2007
Medicare qualified stay Diabetes 1 399 Quinn et al., 2009
Hospice CHF 1 142 Haydar et al., 2004
Advanced medical planning CHF 1 142 Haydar et al., 2004
Use of social services Diabetes 1 789 Sinclair et al., 2000
Costs
Cost MCC 2 1.101 McCormick et al., 2001; Scuvée-Moreau et al., 2002
Cost Diabetes 1 399 Quinn et al., 2009
Medications
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Outcome Chronic condition # of studies Sample size Author, Year
Medications-polypharmacy MCC 7 8,527 Doruk et al., 2010; Lopponen et al., 2005; Lyketsos 
et al., 2005; Lyketsos et al., 2007; Millán-Calenti et 
al., 2011; Wang et al., 2010b; Zekry et al., 2008
Medications-polypharmacy Falls 3 411 Eriksson et al., 2008; Morris et al., 1987; Van Iersel 
et al., 2006
High-risk medications Falls 4 590 Allan et al., 2009; Eriksson et al., 2008; Morris et al., 
1987; Van Iersel et al., 2006
Antidepressants Depression 2 3,228 Blazer et al., 2005; Janzing et al., 2000
Diabetes medications Diabetes 2 1,886 Okura et al., 2009; Sinclair et al., 2000
Osteoporosis medications Hip and other fractures 1 15,718 Vik et al., 2007
Anti Parkinson’s medications Parkinson’s disease 1 130 Aarsland et al., 2001a
Part D Medicare coverage MCC 1 13,160 Zivin et al., 2009
Disease-specific
Disease-specific MCC 6 7,940 Eriksson et al., 2008; García-Lara et al., 2010; 
Magaziner et al., 2005; Rothman et al., 2008; 
Sambrook et al., 2007; Wang et al., 2010c
Disease-specific Cancer 1 258 Robb et al., 2010
Disease-specific Falls 4 1,723 Chen et al., 2005; Chen et al., 2010; Fleming and 
Brayne, 2008; van Iersel et al., 2006
Disease-specific Depression 1 121 Janzing et al., 2000
Disease-specific CVD 1 1,832 Bursi et al., 2006
Disease-specific Diabetes 1 1,097 Okura et al., 2009
Disease-specific Hypertension 1 Vinyoles et al., 2008
Disease-specific Parkinson’s disease 3 555 Aarsland et al., 2001a, 2001b; Melton et al., 2006
Disease-specific Stroke 3 Desmond et al., 1998; Harris et al., 1994; Melkas et 
al., 2009
Function
Function CVD 3 852 Freels et al., 2002; Haydar et al., 2004; Lopponen et 
al., 2005
Function Depression 3 3,517 Feng et al., 2010; Fuhrer et al., 1992a, 1992b; 
Millán-Calenti et al., 2011
Function Diabetes 3 2,285 Okura et al., 2009; Quinn et al., 2009; Sinclair et al., 
2000
Function Falls 3 490 Allan et al., 2009; Eriksson et al., 2008; van Iersel et 
al., 2006
Function Stroke 2 303 Harris et al., 1994; Stott et al., 2001
Function Cancer 1 258 Robb et al., 2010
Function Hypertension 1 782 Huang et al., 2009
CHF, congestive heart failure; CVD, cardiovascular disease; NC, no consensus; MCC, multiple chronic conditions; NH, nursing home.
a
Article citations for each chronic condition-outcome pairing are available by contacting the corresponding author. Some of the 147 studies are 
listed in more than one chronic condition-outcome pairing.
b
At least six expert panelists rated insufficient evidence due to not enough studies (typically 2 or less). Categories with mixed evidence are 
presented in italics.
*
Some studies are described in more then one article (e.g., References 132 and 133 describe the same study)
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